Everolimus Versus Azathioprine in a Cyclosporine and Ketoconazole-Based Immunosuppressive Therapy in Kidney Transplant: 3-Year Follow-up of an Open-Label, Prospective, Cohort, Comparative Clinical Trial

Transplantation Proceedings

Volumn 42, Issue 1, 2010, Pages 270-272

  Gonzalez, F ^b   Espinoza, M ^a   Herrera, P ^a   Rocca, X ^a   Reynolds, E ^b   Lorca, E ^b   Roessler, E ^b   Hidalgo, J ^a   Espinoza, O ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; AZATHIOPRINE; CREATININE; CYCLOSPORIN A; EVEROLIMUS; KETOCONAZOLE; METHYLPREDNISOLONE; PREDNISONE; SIMVASTATIN; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LOADING DRUG DOSE; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL INFECTION; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ADULT; AZATHIOPRINE; CHOLESTEROL; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KETOCONAZOLE; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; TRIGLYCERIDES;

EID: 76749162222     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.12.048     Document Type: Article

References (14)

1. Machado P.G., Felipe C.R., Hanzawa N.M., et al. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination. Clin Transplant 18 (2004) 28
2. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847
3. Kahan B.D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. The Rapamune US Study Group. Lancet 356 (2000) 194
4. Wilkinson G. Drug metabolism and variability among patients in drug response. N Engl J Med 352 (2005) 2211
5. Keogh A., Spratt P., McCosker C., et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 333 (1995) 628
6. Zimmerman J.J. Exposure-response relationships and drug interactions of sirolimus. AAPS J 6 (2004) e28
7. Kovarik J.M., Beyer D., Bizot M.N., et al. Blood concentrations of Everolimus are markedly increased by ketoconazole. J Clin Pharmacol 45 (2005) 514
8. Racusen L.C., Solez K., Colvin R.B., et al. The Banff97 working classification of renal allograft pathology. Kidney Int 55 (1999) 713
9. Cockroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31
10. el-Agroudy A.E., Sobh M.A., Hamdy A.F., et al. A prospective, randomized study of co administration of ketoconazole and cyclosporine A in kidney transplant recipients: ten-year follow-up. Transplantation 77 (2004) 1371
11. Nankivell B.J., Borrows R.J., Fung C.L., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326
12. Baboolal K. A phase III prospective randomized study to evaluate concentration-controlled sirolimus (Rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 75 (2003) 1404
13. Johnson R.W., Kreis H., Oberbauer R., et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72 (2001) 777
14. Pascual J. Everolimus in clinical practice: renal transplantation. Nephrol Dial Transplant 21 Suppl 3 (2006) 8